[Congressional Record Volume 169, Number 152 (Wednesday, September 20, 2023)]
[Senate]
[Page S4633]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 1271. Ms. SINEMA submitted an amendment intended to be proposed to 
amendment SA 1092 proposed by Mrs. Murray (for herself and Ms. Collins) 
to the bill H.R. 4366, making appropriations for military construction, 
the Department of Veterans Affairs, and related agencies for the fiscal 
year ending September 30, 2024, and for other purposes; which was 
ordered to lie on the table; as follows:

       At the appropriate place in division A, insert the 
     following:

     SEC. ___. REPORT ON FEASIBILITY OF STUDY BY DEPARTMENT OF 
                   VETERANS AFFAIRS ON PATIENT RESPONSES TO 
                   PHARMACEUTICALS BASED ON THEIR GENETIC PROFILE.

       (a) In General.--Not later than 90 days after the date of 
     the enactment of this Act, the Secretary of Veterans Affairs 
     shall submit to the appropriate committees of Congress a 
     report on the feasibility, advisability, and cost estimate of 
     undertaking a study to record patient responses to 
     pharmaceuticals based on their genetic profile, which shall 
     include the elements specified under subsection (b).
       (b) Elements of Study.--The elements specified under this 
     subsection are--
       (1) providing a patient with a pharmacogenomics test;
       (2) using the results of that test, through an integrated 
     application programming interface platform, and mapping those 
     results against--
       (A) the medical condition or conditions of the patient;
       (B) the medications currently prescribed to the patient; 
     and
       (C) different therapeutics or medications that are widely 
     prescribed to treat such condition or conditions;
       (3) providing the treating physician of the patient with 
     easily understood, actionable, digitized information to 
     utilize in making a decision about the course of medication 
     or medications that would yield the greatest benefit to the 
     patient and limit the risk of potential harm or adverse 
     events based upon identified drug-to-gene and drug-to-drug 
     interactions; and
       (4) including an analysis on cost saving to the Department 
     of Veterans Affairs and the patient.
       (c) Appropriate Committees of Congress Defined.--In this 
     section, the term ``appropriate committees of Congress'' 
     means--
       (1) the Committee on Appropriations and the Committee on 
     Veterans' Affairs of the Senate; and
       (2) the Committee on Appropriations and the Committee on 
     Veterans' Affairs of the House of Representatives.
                                 ______